NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy ...

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Rising demand for gene and cell therapies, expanding mRNA vaccine pipelines, and increasing investments in GMP-compliant manufacturing facilities are driving growth in the viral vectors and plasmid ...

This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

As of Friday, December 19, BioMarin Pharmaceutical Inc.’s BMRN share price has surged by 14.13%, which has investors questioning if this is right time to sell.

According to the Pan American Health Organization, 7 out of 10 deaths in people over 70 are from non-communicable diseases (NCDs). Aging itself is the single greatest risk factor for the majority of ...

The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read ...

Learn more about whether BioMarin Pharmaceutical Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.

Hemophilia B, a genetic bleeding disorder caused by deficient factor IX activity, has traditionally required lifelong ...